$AMGN (Amgen Inc.) — investor discussion on X

8-K: Item 2.02, Item 9.01

Amgen beats Q3 estimates, raises guidance, shares near 52-week high

Q3 revenue and EPS beat, third guidance raise this year, but Prolia/Xgeva declines weigh on shares

Earnings report

Amgen Q3 Earnings Preview: Market Eyes Rising Costs, Margin Pressure

Pre-earnings coverage highlights expense growth and key metric estimates; stock up 41% YTD

8-K: Item 5.02

Amgen Appoints David W. Gibbs to Board of Directors

New independent director may influence strategic decisions

Amgen to Host Investor Webcast at ESMO 2026

Company to hold investor call on Oct 24 during ESMO congress, showcasing pipeline updates

Tezspire Achieves Histologic Remission and Symptom Improvement in EoE

Week 52 data show statistically significant total endoscopic remission with no visible inflammation or fibrosis

Cantor Fitzgerald Raises Amgen PT to $440, Maintains Neutral

Analyst sees core portfolio upside through 2H, flags debate over MariTide data

AMGN Dazodalibep Phase 3 Positive, Jefferies Raises PT to $410

Phase 3 data corroborated by multiple sources; analyst action confirms positive readout

HSBC downgrades to Hold

AMGN-AZN Combo Shows Survival Benefit in Lung Cancer Study

Imdelltra-Imfinzi combo shows survival benefit in first-line ES-SCLC, broadening market potential

BMO Downgrades AMGN to Market Perform

BMO cites LOE headwinds, growth uncertainty, and need for MariTide clarity

Novartis Lp(a) Drug Phase III Failure Pressures AMGN's Olpasiran

Novartis' pelacarsen misses primary endpoint, raising doubts about AMGN's olpasiran

BMO Capital downgrades to Market Perform

Repatha Cuts Death Risk by 20% in High-Risk Primary Prevention Trial

First PCSK9 inhibitor to show all-cause mortality benefit in primary prevention, potentially strengthening product position

TEZSPIRE Phase 3 Positive in Eosinophilic Esophagitis

Phase 3 met co-primary and key secondary endpoints in EoE, with durable efficacy through Week 52

AMGN Hits 52-Week High, Multiple Funds Boost Stakes

Cane Capital raised stake 73.2%; shares hit new highs alongside MRK, signaling investor interest

Amgen Q2 Revenue Tops $10B, Raises Guidance, Halts Obesity Drug

Multiple sources confirm Q2 beat and raised 2026 outlook despite biosimilar pressure

Amgen and others to report earnings after tomorrow's close

Multiple sources mention Amgen's earnings timing, market watches results

Amgen Discloses Data Breach, Patient Information Stolen

Law firm investigates patient data exposure, ongoing legal action

Earnings report

8-K: Item 2.02, Item 9.01

8-K: Item 1.05

European CHMP Supports Broader Use of Repatha® Before First Heart Attack or Stroke

EMA's CHMP issued positive opinion supporting expanded indication for Repatha